Albemarle Reports Second-Quarter Results

 
 

ALBemarle Corporation (NYSE: ALB) today announced its results for the second quarter ended June 30, 2021 .

 
 

  Albemarle Corp. Logo. (PRNewsFoto/Albemarle Corporation) 

 
 

  Second Quarter 2021 Highlights
  (Unless otherwise stated, all percent changes are based on year-over-year comparisons)  

 
  • Net income of $424.6 million , or $3.62 per diluted share, including a gain on the sale of Fine Chemistry Services (FCS) business
  •  
  • Adjusted diluted EPS of $0.89 , an increase of 4%
  •  
  • Net sales of $773.9 million , an increase of 1%; Net sales increased 5% excluding FCS
  •  
  • Adjusted EBITDA of $194.6 million , an increase of 5%; Adjusted EBITDA increased 13% excluding FCS
  •  
  • Full year 2021 outlook revised to reflect better than expected Lithium performance, lower interest expense and tax rates, offset by higher Bromine raw material costs and supply chain disruptions; guidance updated to reflect sale of FCS
  •  
  • Completed the sale of FCS on June 1, 2021 , in a cash and stock transaction valued at ~$570 million  
  •  
  • La Negra III/IV commissioning stage in process, commercial production expected to begin in first half of 2022
  •  

"  Albemarle  delivered another strong quarter, generating $195 million in adjusted EBITDA, driven by continued strength in demand for our Lithium and Bromine products," said Albemarle CEO Kent Masters . "We are focused on executing our accelerated growth strategy. We are in the final stages of two lithium projects which are expected to double our nameplate capacity to about 175,000 metric tons, including La Negra III/IV where construction is complete and commissioning is progressing. We are firmly focused on advancing all our lithium projects to meet customer demand and accelerate profitable growth."

 

  Outlook  

 

The company continues to expect a modest improvement in operating performance compared to full year 2020, assuming continued global economic recovery. Full-year 2021 net sales guidance is improved compared to previous guidance primarily due to increased Lithium sales and improving Catalysts trends offset by reduced expectations for the Bromine business as a result of higher raw material costs and supply chain disruptions.  Revised EBITDA reflects higher net sales offset by higher corporate costs, primarily related to incentive compensation expense and foreign exchange.  Higher EPS and net cash from operations reflects lower interest expense and tax rates.  Net cash from operations is also expected to benefit from timing of working capital changes.  Capital expenditures are trending near the high-end of the range, due to tighter labor markets and COVID-related travel restrictions in Western Australia.  Pro forma revised guidance has been updated to reflect the sale of Albemarle's Fine Chemistry Services (FCS) business to W. R. Grace, which closed on June 1, 2021 .

 
 
                                                
 
 

   Revised   

 
 
 

   FCS Adjustment   

 
 
 

   Pro Forma Revised   

 
 
 

   FY 2021 Guidance   

 
 
 

   (Jun 1 - Dec 31, 2021)   

 
 
 

   FY 2021 Guidance   

 
 

  Net sales  

 
 

  $3.3 - $3.4 billion  

 
 
 

  $95 - $105 million  

 
 
 

  $3.2 - $3.3 billion  

 
 

  Adjusted EBITDA  

 
 

  $810 - $860 million  

 
 
 

  $35 - $45 million  

 
 
 

  $775 - $815 million  

 
 

  Adjusted EBITDA Margin  

 
 

  24% - 25%  

 
 
 
 
 

  24% - 25%  

 
 

  Adjusted Diluted EPS  

 
 

  $3.60 - $4.00  

 
 
 

  $0.25 - $0.30  

 
 
 

  $3.35 - $3.70  

 
 

  Net Cash from Operations  

 
 

  $590 - $690 million  

 
 
 

  $40 - $45 million  

 
 
 

  $550 - $650 million  

 
 

  Capital Expenditures  

 
 

  $850 - $950 million  

 
 
 

  $4 - $8 million  

 
 
 

  $850 - $950 million  

 
 
 

  COVID-19 Response  

 

  Albemarle's cross-functional Global Response Team continues to meet regularly to address employee health and safety and operational challenges. The company's priority is always the health and well-being of its employees, customers, and communities. The company continues to focus on building in the flexibility needed to adjust for regional differences and changing conditions.

 

  Second-Quarter Results  

 
 
                                                                                                       
 

   In millions, except per share amounts   

 
 

   Q2 2021   

 
 
 

   Q2 2020   

 
 
 

   $ Change   

 
 
 

   % Change   

 
 

  Net sales  

 
 

  $  

 
 

  773.9  

 
 
 
 

  $  

 
 

  764.0  

 
 
 
 

  $  

 
 

  9.8  

 
 
 
 

  1.3  

 
 

  %  

 
 

  Net income attributable to Albemarle Corporation  

 
 

  $  

 
 

  424.6  

 
 
 
 

  $  

 
 

  85.6  

 
 
 
 

  $  

 
 

  339.0  

 
 
 
 

  395.9  

 
 

  %  

 
 

  Adjusted EBITDA (a)  

 
 

  $  

 
 

  194.6  

 
 
 
 

  $  

 
 

  185.2  

 
 
 
 

  $  

 
 

  9.4  

 
 
 
 

  5.1  

 
 

  %  

 
 

  Diluted earnings per share  

 
 

  $  

 
 

  3.62  

 
 
 
 

  $  

 
 

  0.80  

 
 
 
 

  $  

 
 

  2.82  

 
 
 
 

  352.5  

 
 

  %  

 
 

  Non-operating pension and OPEB items (a)  

 
 

  (0.04)  

 
 
 
 

  (0.02)  

 
 
 
 
 
 
 

  Non-recurring and other unusual items (a)  

 
 

  (2.69)  

 
 
 
 

  0.07  

 
 
 
 
 
 
 

  Adjusted diluted earnings per share (b)  

 
 

  $  

 
 

  0.89  

 
 
 
 

  $  

 
 

  0.86  

 
 
 
 

  $  

 
 

  0.03  

 
 
 
 

  3.5  

 
 

  %  

 
 
 
 
      
 
 
 

  (a)  

 
 

  See Non-GAAP Reconciliations for further details.  

 
 

  (b)  

 
 

  Totals may not add due to rounding.  

 
 
 

Net sales of $773.9 million increased by $9.8 million compared to the prior year quarter, primarily driven by an increase in sales from the company's Lithium and Bromine business segments. Excluding the FCS business, net sales for the quarter increased 5% year-over-year.

 

Adjusted EBITDA of $194.6 million increased by $9.4 million from the prior year quarter based on higher sales and operating margins, partially offset by higher corporate expense primarily related to higher incentive compensation and foreign exchange. Excluding FCS, adjusted EBITDA was 13% higher when compared to the second quarter of 2020. Net income attributable to Albemarle of $424.6 million increased by $339.0 million , benefiting from a $429.4 million ( $331.6 million after taxes) gain on the sale of the company's FCS business.

 

The effective income tax rate for the second quarter of 2021 was 20.0% compared to 17.5% in the same period of 2020. The difference is largely due to tax expense recorded in the second quarter of 2021 for the gain on the sale of the FCS business. On an adjusted basis, the effective income tax rates were 17.5% and 18.9% for the second quarter of 2021 and 2020, respectively.

 

  Business Segment Results  

 

  Lithium  

 
 
                                      
 

   In millions   

 
 

   Q2 2021   

 
 
 

   Q2 2020   

 
 
 

   $ Change   

 
 
 

   % Change   

 
 

  Net Sales  

 
 

  $  

 
 

  320.3  

 
 
 
 

  $  

 
 

  283.7  

 
 
 
 

  $  

 
 

  36.6  

 
 
 
 

  12.9  

 
 

  %  

 
 

  Adjusted EBITDA  

 
 

  $  

 
 

  109.4  

 
 
 
 

  $  

 
 

  94.5  

 
 
 
 

  $  

 
 

  14.9  

 
 
 
 

  15.8  

 
 

  %  

 
 
 

Lithium net sales of $320.3 million increased $36.6 million (+13%) primarily driven by higher volumes (+17%) primarily related to accelerated orders under long-term agreements. Pricing in the quarter was slightly lower year over year (-4%) due to lower average pricing for carbonate and technical grade products. Adjusted EBITDA of $109.4 million increased $14.9 million primarily due to increased net sales and the impact of higher spodumene volumes at the Talison joint venture.

 

   Current Trends:   Full-year 2021 volume growth is expected to be in the mid-teens year-over-year due to North American plant restarts, productivity improvements, and tolling. Average realized pricing is expected to increase sequentially but remain flat compared to 2020. Full-year 2021 adjusted EBITDA is expected to grow between 10% and 15% year over year. Full-year 2021 average margin is expected to remain below 35% due to higher lithium costs related to project start-ups and tolling costs partially offset by efficiency improvements.

 

  Albemarle's Wave 2 growth projects continue to progress.  La Negra III/IV is in the commissioning phase and Kemerton I remains on track for construction completion later this year. To mitigate risks related to labor shortages and COVID-19 travel restrictions in Western Australia , the company prioritized completion of Kemerton I, with Kemerton II construction completion now expected by the end of the first quarter 2022. Kemerton I and II are expected to reach commercial production in 2022 following an approximately six month commissioning and qualification period.

 

  Bromine Specialties  

 
 
                                      
 

   In millions   

 
 

   Q2 2021   

 
 
 

   Q2 2020   

 
 
 

   $ Change   

 
 
 

   % Change   

 
 

  Net Sales  

 
 

  $  

 
 

  279.7  

 
 
 
 

  $  

 
 

  232.8  

 
 
 
 

  $  

 
 

  47.0  

 
 
 
 

  20.2  

 
 

  %  

 
 

  Adjusted EBITDA  

 
 

  $  

 
 

  92.6  

 
 
 
 

  $  

 
 

  73.0  

 
 
 
 

  $  

 
 

  19.6  

 
 
 
 

  26.8  

 
 

  %  

 
 
 

Bromine net sales of $279.7 million increased $47.0 million (+20%) with improved pricing (+9%) and volumes (+11%) driven by higher demand across the portfolio.  Adjusted EBITDA of $92.6 million increased $19.6 million due to higher net sales. Cost savings initiatives and higher pricing helped offset raw materials cost increases.

 

   Current Trends:   The company expects full-year 2021 adjusted EBITDA growth in the mid-single digits year-over-year, below previous outlook primarily due to a force majeure declaration by our chlorine supplier in the U.S. The company continues to see strength in certain end markets, including electronics, and building and construction. Volumes are also expected to be lower in the second half due to inventory drawdown and reduced production related to the U.S. Gulf Coast winter storms in the first quarter of 2021. Cost savings and higher pricing partially offset inflation in raw materials and freight.

 

  Catalysts  

 
 
                                      
 

   In millions   

 
 

   Q2 2021   

 
 
 

   Q2 2020   

 
 
 

   $ Change   

 
 
 

   % Change   

 
 

  Net Sales  

 
 

  $  

 
 

  148.3  

 
 
 
 

  $  

 
 

  197.1  

 
 
 
 

  $  

 
 

  (48.7)  

 
 
 
 

  (24.7)  

 
 

  %  

 
 

  Adjusted EBITDA  

 
 

  $  

 
 

  21.2  

 
 
 
 

  $  

 
 

  22.8  

 
 
 
 

  $  

 
 

  (1.6)  

 
 
 
 

  (7.1)  

 
 

  %  

 
 
 

Catalysts net sales of $148.3 million decreased $48.7 million (-25%) compared to the previous year, primarily due to lower volumes (-25%) while pricing was flat. Clean Fuels Technologies (CFT) volumes decreased due to timing of shipments. Fluid Catalytic Cracking (FCC) volumes were down slightly versus prior year, as a change in order patterns from a large North American customer offset generally higher FCC demand.  Performance Catalyst Solutions (PCS) results improved due to product mix. Adjusted EBITDA of $21.2 million declined $1.6 million mostly due to lower sales. Also, second quarter 2020 results were understated by $12.0 million due to an out-of-period correction to cost of goods sold for inventory values.

 

   Current Trends:   The company continues to expect full-year 2021 adjusted EBITDA to decline by between 30% and 40%.  Market conditions are improving, but results are expected to be down from prior year primarily due to the impact of the U.S. Gulf Coast winter storm, product mix, and the previously disclosed change in order patterns from a large North American customer.

 

  All Other  

 
 
                                      
 

   In millions   

 
 

   Q2 2021   

 
 
 

   Q2 2020   

 
 
 

   $ Change   

 
 
 

   % Change   

 
 

  Net Sales  

 
 

  $  

 
 

  25.5  

 
 
 
 

  $  

 
 

  50.5  

 
 
 
 

  $  

 
 

  (25.0)  

 
 
 
 

  (49.6)  

 
 

  %  

 
 

  Adjusted EBITDA  

 
 

  $  

 
 

  8.4  

 
 
 
 

  $  

 
 

  18.6  

 
 
 
 

  $  

 
 

  (10.2)  

 
 
 
 

  (54.9)  

 
 

  %  

 
 
 

Other operations represents the company's recently sold FCS business. FCS net sales of $25.5 million declined $25.0 million and adjusted EBITDA of $8.4 million declined $10.2 million . Second-quarter 2021 results include only two months of performance following the sale of FCS on June 1, 2021 . Albemarle recorded a gain of $429.4 million ( $331.6 million after taxes) related to the sale of the FCS business.

 

  Balance Sheet and Liquidity  

 

As of June 30, 2021 , Albemarle had estimated liquidity of approximately $2.2 billion , including $823.6 million of cash and equivalents, the full $1.0 billion available under the company's revolver, $270.0 million remaining under its delayed draw term loan and $132.0 million on other available credit lines. Total debt was $2.0 billion , representing net debt to adjusted EBITDA of approximately 1.5 times.

 

  Cash Flow and Capital Deployment  

 

Cash from operations for the six months ended June 30, 2021 , of $385.9 million increased $177.9 million versus the prior year driven by working capital inflows and higher revenues in the company's Lithium and Bromine segments. Capital expenditures of $396.9 million decreased by approximately $22.0 million versus the prior year as the company nears completion of its Wave 2 Lithium expansion projects.

 

  Albemarle's primary capital allocation priorities are to grow profitably, fund its dividend, and maintain its financial flexibility and our Investment Grade credit rating.

 

In May, the board declared a quarterly dividend of $0.39 per share, an increase over the quarterly dividend paid in 2020. This is Albemarle's 27th consecutive year of dividend increases. The share repurchase authorization remains in place; however, the company has no near-term plans to execute share buybacks.

 

  Earnings Call  

 
 
          
 

  Date:  

 
 

  Thursday, August 5, 2021  

 
 

  Time:  

 
 

  9:00 AM Eastern time  

 
 

  Dial-in (U.S.):  

 
 

  844-347-1034  

 
 

  Dial-in (International):  

 
 

  209-905-5910  

 
 

  Passcode:  

 
 

  6747789  

 
 
 

The company's earnings presentation and supporting material are available on Albemarle's website at https://investors.albemarle.com .

 

  About Albemarle   

 

 ALBemarle Corporation (NYSE: ALB) is a global specialty chemicals company with leading positions in lithium, bromine and refining catalysts. We think beyond business-as-usual to power the potential of companies in many of the world's largest and most critical industries, such as energy, electronics, and transportation. We actively pursue a sustainable approach to managing our diverse global footprint of world-class resources. In conjunction with our highly experienced and talented global teams, our deep-seated values, and our collaborative customer relationships, we create value-added and performance-based solutions that enable a safer and more sustainable future.

 

We regularly post information to www.albemarle.com , including notification of events, news, financial performance, investor presentations and webcasts, non-GAAP reconciliations, SEC filings and other information regarding our company, its businesses and the markets it serves.

 

  Forward-Looking Statements  

 

Some of the information presented in this press release, the conference call and discussions that follow, including, without limitation, information related to the timing of active and proposed projects, product development, production capacity, committed volumes, market trends, pricing, financial flexibility, expected growth, anticipated return on opportunities, earnings and demand for our products, input costs, productivity improvements, surcharges, tax rates, stock repurchases, dividends, cash flow generation, costs and cost synergies, capital projects, future acquisition and divestiture transactions, expected benefits from proposed transactions, economic trends, outlook and all other information relating to matters that are not historical facts may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the views expressed. Factors that could cause actual results to differ materially from the outlook expressed or implied in any forward-looking statement include, without limitation: changes in economic and business conditions; changes in financial and operating performance of our major customers and industries and markets served by us; the timing of orders received from customers; the gain or loss of significant customers; competition from other manufacturers; changes in the demand for our products or the end-user markets in which our products are sold; limitations or prohibitions on the manufacture and sale of our products; availability of raw materials; increases in the cost of raw materials and energy, and our ability to pass through such increases to our customers; changes in our markets in general; fluctuations in foreign currencies; changes in laws and government regulation impacting our operations or our products; the occurrence of regulatory actions, proceedings, claims or litigation; the occurrence of cyber-security breaches, terrorist attacks, industrial accidents, natural disasters or climate change; hazards associated with chemicals manufacturing; the inability to maintain current levels of product or premises liability insurance or the denial of such coverage; political unrest affecting the global economy, including adverse effects from terrorism or hostilities; political instability affecting our manufacturing operations or joint ventures; changes in accounting standards; the inability to achieve results from our global manufacturing cost reduction initiatives as well as our ongoing continuous improvement and rationalization programs; changes in the jurisdictional mix of our earnings and changes in tax laws and rates; changes in monetary policies, inflation or interest rates that may impact our ability to raise capital or increase our cost of funds, impact the performance of our pension fund investments and increase our pension expense and funding obligations; volatility and uncertainties in the debt and equity markets; technology or intellectual property infringement, including cyber-security breaches, and other innovation risks; decisions we may make in the future; the ability to successfully execute, operate and integrate acquisitions and divestitures; uncertainties as to the duration and impact of the coronavirus (COVID-19) pandemic; and the other factors detailed from time to time in the reports we file with the SEC, including those described under "Risk Factors" in our most recent Annual Report on Form 10-K any subsequently filed Quarterly Reports on Form 10-Q. These forward-looking statements speak only as of the date of this press release. We assume no obligation to provide any revisions to any forward-looking statements should circumstances change, except as otherwise required by securities and other applicable laws.

 

 

 

Albemarle Corporation and Subsidiaries
Consolidated Statements of Income
(In Thousands Except Per Share Amounts) (Unaudited)

 
 
                                                                                                                                                                                                                                                                                        
 
 

   Three Months Ended   

 
 
 

   Six Months Ended   

 
 
 

   June 30,   

 
 
 

   June 30,   

 
 
 

   2021   

 
 
 

   2020   

 
 
 

   2021   

 
 
 

   2020   

 
 

   Net sales   

 
 

  $  

 
 

  773,896  

 
 
 
 

  $  

 
 

  764,049  

 
 
 
 

  $  

 
 

  1,603,187  

 
 
 
 

  $  

 
 

  1,502,894  

 
 
 

  Cost of goods sold  

 
 

  525,479  

 
 
 
 

  530,690  

 
 
 
 

  1,091,083  

 
 
 
 

  1,027,517  

 
 
 

   Gross profit   

 
 

  248,417  

 
 
 
 

  233,359  

 
 
 
 

  512,104  

 
 
 
 

  475,377  

 
 
 

  Selling, general and administrative expenses  

 
 

  121,516  

 
 
 
 

  106,949  

 
 
 
 

  214,703  

 
 
 
 

  208,826  

 
 
 

  Research and development expenses  

 
 

  13,976  

 
 
 
 

  14,210  

 
 
 
 

  28,612  

 
 
 
 

  30,307  

 
 
 

  Gain on sale of business  

 
 

  (429,408)  

 
 
 
 

  

 
 
 
 

  (429,408)  

 
 
 
 

  

 
 
 

   Operating profit   

 
 

  542,333  

 
 
 
 

  112,200  

 
 
 
 

  698,197  

 
 
 
 

  236,244  

 
 
 

  Interest and financing expenses  

 
 

  (7,152)  

 
 
 
 

  (17,852)  

 
 
 
 

  (51,034)  

 
 
 
 

  (34,737)  

 
 
 

  Other income (expense), net  

 
 

  14  

 
 
 
 

  (6,273)  

 
 
 
 

  11,326  

 
 
 
 

  2,041  

 
 
 

  Income before income taxes and equity in net income of unconsolidated investments  

 
 

  535,195  

 
 
 
 

  88,075  

 
 
 
 

  658,489  

 
 
 
 

  203,548  

 
 
 

  Income tax expense  

 
 

  106,985  

 
 
 
 

  15,431  

 
 
 
 

  129,092  

 
 
 
 

  33,873  

 
 
 

  Income before equity in net income of unconsolidated investments  

 
 

  428,210  

 
 
 
 

  72,644  

 
 
 
 

  529,397  

 
 
 
 

  169,675  

 
 
 

  Equity in net income of unconsolidated investments (net of tax)  

 
 

  17,998  

 
 
 
 

  31,114  

 
 
 
 

  34,509  

 
 
 
 

  57,718  

 
 
 

  Net income  

 
 

  446,208  

 
 
 
 

  103,758  

 
 
 
 

  563,906  

 
 
 
 

  227,393  

 
 
 

  Net income attributable to noncontrolling interests  

 
 

  (21,608)  

 
 
 
 

  (18,134)  

 
 
 
 

  (43,629)  

 
 
 
 

  (34,565)  

 
 
 

  Net income attributable to Albemarle Corporation  

 
 

  $  

 
 

  424,600  

 
 
 
 

  $  

 
 

  85,624  

 
 
 
 

  $  

 
 

  520,277  

 
 
 
 

  $  

 
 

  192,828  

 
 
 

  Basic earnings per share  

 
 

  $  

 
 

  3.63  

 
 
 
 

  $  

 
 

  0.81  

 
 
 
 

  $  

 
 

  4.54  

 
 
 
 

  $  

 
 

  1.81  

 
 
 

  Diluted earnings per share  

 
 

  $  

 
 

  3.62  

 
 
 
 

  $  

 
 

  0.80  

 
 
 
 

  $  

 
 

  4.51  

 
 
 
 

  $  

 
 

  1.81  

 
 
 
 
 
 
 
 
 
 
 

  Weighted-average common shares outstanding – basic  

 
 

  116,809  

 
 
 
 

  106,329  

 
 
 
 

  114,700  

 
 
 
 

  106,278  

 
 
 

  Weighted-average common shares outstanding – diluted  

 
 

  117,436  

 
 
 
 

  106,535  

 
 
 
 

  115,383  

 
 
 
 

  106,524  

 
 
 
 

 

 

Albemarle Corporation and Subsidiaries
Condensed Consolidated Balance Sheets
(In Thousands) (Unaudited)

 
 
                                                                                                                                                                                                                                                  
 
 

   June 30,   

 
 
 

   December 31,   

 
 
 

   2021   

 
 
 

   2020   

 
 

   ASSETS   

 
 
 
 
 

  Current assets:  

 
 
 
 
 

  Cash and cash equivalents  

 
 

  $  

 
 

  823,572  

 
 
 
 

  $  

 
 

  746,724  

 
 
 

  Trade accounts receivable  

 
 

  455,222  

 
 
 
 

  530,838  

 
 
 

  Other accounts receivable  

 
 

  58,256  

 
 
 
 

  61,958  

 
 
 

  Inventories  

 
 

  732,563  

 
 
 
 

  750,237  

 
 
 

  Other current assets  

 
 

  81,741  

 
 
 
 

  116,427  

 
 
 

  Total current assets  

 
 

  2,151,354  

 
 
 
 

  2,206,184  

 
 
 

  Property, plant and equipment  

 
 

  7,596,684  

 
 
 
 

  7,427,641  

 
 
 

  Less accumulated depreciation and amortization  

 
 

  2,086,085  

 
 
 
 

  2,073,016  

 
 
 

  Net property, plant and equipment  

 
 

  5,510,599  

 
 
 
 

  5,354,625  

 
 
 

  Investments  

 
 

  907,080  

 
 
 
 

  656,244  

 
 
 

  Other assets  

 
 

  256,081  

 
 
 
 

  219,268  

 
 
 

  Goodwill  

 
 

  1,640,720  

 
 
 
 

  1,665,520  

 
 
 

  Other intangibles, net of amortization  

 
 

  331,092  

 
 
 
 

  349,105  

 
 
 

  Total assets  

 
 

  $  

 
 

  10,796,926  

 
 
 
 

  $  

 
 

  10,450,946  

 
 
 

   LIABILITIES AND EQUITY   

 
 
 
 
 

  Current liabilities:  

 
 
 
 
 

  Accounts payable  

 
 

  $  

 
 

  535,153  

 
 
 
 

  $  

 
 

  483,221  

 
 
 

  Accrued expenses  

 
 

  317,954  

 
 
 
 

  440,763  

 
 
 

  Current portion of long-term debt  

 
 

  623  

 
 
 
 

  804,677  

 
 
 

  Dividends payable  

 
 

  45,428  

 
 
 
 

  40,937  

 
 
 

  Income taxes payable  

 
 

  85,770  

 
 
 
 

  32,251  

 
 
 

  Total current liabilities  

 
 

  984,928  

 
 
 
 

  1,801,849  

 
 
 

  Long-term debt  

 
 

  2,043,794  

 
 
 
 

  2,767,381  

 
 
 

  Postretirement benefits  

 
 

  47,371  

 
 
 
 

  48,075  

 
 
 

  Pension benefits  

 
 

  309,712  

 
 
 
 

  340,818  

 
 
 

  Other noncurrent liabilities  

 
 

  616,912  

 
 
 
 

  629,377  

 
 
 

  Deferred income taxes  

 
 

  428,438  

 
 
 
 

  394,852  

 
 
 

  Commitments and contingencies  

 
 
 
 
 

  Equity:  

 
 
 
 
 

  Albemarle Corporation shareholders' equity:  

 
 
 
 
 

  Common stock  

 
 

  1,169  

 
 
 
 

  1,069  

 
 
 

  Additional paid-in capital  

 
 

  2,907,981  

 
 
 
 

  1,438,038  

 
 
 

  Accumulated other comprehensive loss  

 
 

  (328,001)  

 
 
 
 

  (326,132)  

 
 
 

  Retained earnings  

 
 

  3,584,400  

 
 
 
 

  3,155,252  

 
 
 

  Total Albemarle Corporation shareholders' equity  

 
 

  6,165,549  

 
 
 
 

  4,268,227  

 
 
 

  Noncontrolling interests  

 
 

  200,222  

 
 
 
 

  200,367  

 
 
 

  Total equity  

 
 

  6,365,771  

 
 
 
 

  4,468,594  

 
 
 

  Total liabilities and equity  

 
 

  $  

 
 

  10,796,926  

 
 
 
 

  $  

 
 

  10,450,946  

 
 
 
 

 

 

Albemarle Corporation and Subsidiaries
Selected Consolidated Cash Flow Data
(In Thousands) (Unaudited)

 
 
                                                                                                                                                                                                                                                  
 
 

   Six Months Ended   

 

   June 30,   

 
 
 

   2021   

 
 
 

   2020   

 
 

  Cash and cash equivalents at beginning of year  

 
 

  $  

 
 

  746,724  

 
 
 
 

  $  

 
 

  613,110  

 
 
 

  Cash flows from operating activities:  

 
 
 
 
 

  Net income  

 
 

  563,906  

 
 
 
 

  227,393  

 
 
 

  Adjustments to reconcile net income to cash flows from operating activities:  

 
 
 
 
 

  Depreciation and amortization  

 
 

  123,683  

 
 
 
 

  111,535  

 
 
 

  Gain on sale of business  

 
 

  (429,408)  

 
 
 
 

  

 
 
 

  Stock-based compensation and other  

 
 

  8,425  

 
 
 
 

  9,765  

 
 
 

  Equity in net income of unconsolidated investments (net of tax)  

 
 

  (34,509)  

 
 
 
 

  (57,718)  

 
 
 

  Dividends received from unconsolidated investments and nonmarketable securities  

 
 

  27,420  

 
 
 
 

  12,984  

 
 
 

  Pension and postretirement benefit  

 
 

  (8,465)  

 
 
 
 

  (3,312)  

 
 
 

  Pension and postretirement contributions  

 
 

  (20,266)  

 
 
 
 

  (6,692)  

 
 
 

  Unrealized gain on investments in marketable securities  

 
 

  (2,384)  

 
 
 
 

  (1,278)  

 
 
 

  Loss on early extinguishment of debt  

 
 

  28,955  

 
 
 
 

  

 
 
 

  Deferred income taxes  

 
 

  27,708  

 
 
 
 

  8,990  

 
 
 

  Working capital changes  

 
 

  7,942  

 
 
 
 

  (156,579)  

 
 
 

  Non-cash transfer of 40% value of construction in progress of Kemerton plant to MRL  

 
 

  96,185  

 
 
 
 

  87,750  

 
 
 

  Other, net  

 
 

  (3,339)  

 
 
 
 

  (24,921)  

 
 
 

  Net cash provided by operating activities  

 
 

  385,853  

 
 
 
 

  207,917  

 
 
 

  Cash flows from investing activities:  

 
 
 
 
 

  Acquisitions, net of cash acquired  

 
 

  

 
 
 
 

  (22,572)  

 
 
 

  Capital expenditures  

 
 

  (396,915)  

 
 
 
 

  (418,991)  

 
 
 

  Cash proceeds from divestitures, net  

 
 

  290,467  

 
 
 
 

  

 
 
 

  Sales of marketable securities, net  

 
 

  4,553  

 
 
 
 

  1,496  

 
 
 

  Investments in equity and other corporate investments  

 
 

  (286)  

 
 
 
 

  (486)  

 
 
 

  Net cash used in investing activities  

 
 

  (102,181)  

 
 
 
 

  (440,553)  

 
 
 

  Cash flows from financing activities:  

 
 
 
 
 

  Proceeds from issuance of common stock  

 
 

  1,453,888  

 
 
 
 

  

 
 
 

  Repayments of long-term debt and credit agreements  

 
 

  (1,173,823)  

 
 
 
 

  

 
 
 

  Proceeds from borrowings of credit agreements  

 
 

  

 
 
 
 

  452,163  

 
 
 

  Other debt repayments, net  

 
 

  (325,316)  

 
 
 
 

  12,956  

 
 
 

  Fees related to early extinguishment of debt  

 
 

  (24,877)  

 
 
 
 

  

 
 
 

  Dividends paid to shareholders  

 
 

  (86,637)  

 
 
 
 

  (79,909)  

 
 
 

  Dividends paid to noncontrolling interests  

 
 

  (43,698)  

 
 
 
 

  (14,286)  

 
 
 

  Proceeds from exercise of stock options  

 
 

  14,335  

 
 
 
 

  10,809  

 
 
 

  Withholding taxes paid on stock-based compensation award distributions  

 
 

  (7,047)  

 
 
 
 

  (4,019)  

 
 
 

  Other  

 
 

  (1,359)  

 
 
 
 

  (2,669)  

 
 
 

  Net cash (used in) provided by financing activities  

 
 

  (194,534)  

 
 
 
 

  375,045  

 
 
 

  Net effect of foreign exchange on cash and cash equivalents  

 
 

  (12,290)  

 
 
 
 

  (18,823)  

 
 
 

  Increase in cash and cash equivalents  

 
 

  76,848  

 
 
 
 

  123,586  

 
 
 

  Cash and cash equivalents at end of period  

 
 

  $  

 
 

  823,572  

 
 
 
 

  $  

 
 

  736,696  

 
 
 
 

 

 

Albemarle Corporation and Subsidiaries
Consolidated Summary of Segment Results
(In Thousands) (Unaudited)

 
 
                                                                                                                                                                                            
 
 

   Three Months Ended   

 
 
 

   Six Months Ended   

 
 
 

   June 30,   

 
 
 

   June 30,   

 
 
 

   2021   

 
 
 

   2020   

 
 
 

   2021   

 
 
 

   2020   

 
 

   Net sales:   

 
 
 
 
 
 
 
 
 

  Lithium  

 
 

  $  

 
 

  320,334  

 
 
 
 

  $  

 
 

  283,722  

 
 
 
 

  $  

 
 

  599,310  

 
 
 
 

  $  

 
 

  520,540  

 
 
 

  Bromine Specialties  

 
 

  279,748  

 
 
 
 

  232,779  

 
 
 
 

  560,195  

 
 
 
 

  464,371  

 
 
 

  Catalysts  

 
 

  148,344  

 
 
 
 

  197,053  

 
 
 
 

  368,587  

 
 
 
 

  404,260  

 
 
 

  All Other  

 
 

  25,470  

 
 
 
 

  50,495  

 
 
 
 

  75,095  

 
 
 
 

  113,723  

 
 
 

  Total net sales  

 
 

  $  

 
 

  773,896  

 
 
 
 

  $  

 
 

  764,049  

 
 
 
 

  $  

 
 

  1,603,187  

 
 
 
 

  $  

 
 

  1,502,894  

 
 
 
 
 
 
 
 
 
 
 

   Adjusted EBITDA:   

 
 
 
 
 
 
 
 
 

  Lithium  

 
 

  $  

 
 

  109,441  

 
 
 
 

  $  

 
 

  94,536  

 
 
 
 

  $  

 
 

  215,877  

 
 
 
 

  $  

 
 

  173,173  

 
 
 

  Bromine Specialties  

 
 

  92,646  

 
 
 
 

  73,041  

 
 
 
 

  187,286  

 
 
 
 

  156,303  

 
 
 

  Catalysts  

 
 

  21,164  

 
 
 
 

  22,777  

 
 
 
 

  46,591  

 
 
 
 

  70,247  

 
 
 

  All Other  

 
 

  8,379  

 
 
 
 

  18,598  

 
 
 
 

  29,858  

 
 
 
 

  41,422  

 
 
 

  Corporate  

 
 

  (37,002)  

 
 
 
 

  (23,759)  

 
 
 
 

  (54,930)  

 
 
 
 

  (59,587)  

 
 
 

  Total adjusted EBITDA  

 
 

  $  

 
 

  194,628  

 
 
 
 

  $  

 
 

  185,193  

 
 
 
 

  $  

 
 

  424,682  

 
 
 
 

  $  

 
 

  381,558  

 
 
 
 

See accompanying non-GAAP reconciliations below.

 

  Additional Information  

 

It should be noted that adjusted net income attributable to Albemarle Corporation, adjusted diluted earnings per share, non-operating pension and OPEB items per diluted share, non-recurring and other unusual items per diluted share, adjusted effective income tax rates, EBITDA, adjusted EBITDA, EBITDA margin and adjusted EBITDA margin are financial measures that are not required by, or presented in accordance with, accounting principles generally accepted in the United States , or GAAP. These non-GAAP measures should not be considered as alternatives to Net income attributable to Albemarle Corporation ("earnings") or other comparable measures calculated and reported in accordance with GAAP. These measures are presented here to provide additional useful measurements to review the company's operations, provide transparency to investors and enable period-to-period comparability of financial performance. The company's chief operating decision maker uses these measures to assess the ongoing performance of the company and its segments, as well as for business and enterprise planning purposes.

 

A description of other non-GAAP financial measures that Albemarle uses to evaluate its operations and financial performance, and reconciliation of these non-GAAP financial measures to the most directly comparable financial measures calculated and reported in accordance with GAAP can be found on the following pages of this press release, which is also is available on Albemarle's website at https://investors.albemarle.com . The company does not provide a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable financial measures calculated and reported in accordance with GAAP, as the company is unable to estimate significant non-recurring or unusual items without unreasonable effort. The amounts and timing of these items are uncertain and could be material to the company's results calculated in accordance with GAAP.

 

   ALBEMARLE CORPORATION AND SUBSIDIARIES
  Non-GAAP Reconciliations
  (Unaudited)  

 

See below for a reconciliation of adjusted net income attributable to Albemarle Corporation, EBITDA and adjusted EBITDA, the non-GAAP financial measures, to Net income attributable to Albemarle Corporation ("earnings"), the most directly comparable financial measure calculated and reported in accordance with GAAP. Adjusted earnings is defined as earnings before the non-recurring, other unusual and non-operating pension and other post-employment benefit (OPEB) items as listed below. The non-recurring and unusual items may include acquisition and integration related costs, gains or losses on sales of businesses, restructuring charges, facility divestiture charges and other significant non-recurring items. EBITDA is defined as earnings before interest and financing expenses, income taxe expense, and depreciation and amortization. Adjusted EBITDA is defined as EBITDA plus or minus the non-recurring, other unusual and non-operating pension and OPEB items as listed below.

 
 
                                                                                                                                                                                                                                                                                                    
 
 

   Three Months Ended   

 
 
 

   Six Months Ended   

 
 
 

   June 30,   

 
 
 

   June 30,   

 
 

   In thousands, except percentages and per share amounts   

 
 

   2021   

 
 
 

   2020   

 
 
 

   2021   

 
 
 

   2020   

 
 

  Net income attributable to Albemarle Corporation  

 
 

  $  

 
 

  424,600  

 
 
 
 

  $  

 
 

  85,624  

 
 
 
 

  $  

 
 

  520,277  

 
 
 
 

  $  

 
 

  192,828  

 
 
 

  Add back:  

 
 
 
 
 
 
 
 
 

  Non-operating pension and OPEB items (net of tax)  

 
 

  (4,273)  

 
 
 
 

  (2,299)  

 
 
 
 

  (8,540)  

 
 
 
 

  (4,610)  

 
 
 

  Non-recurring and other unusual items (net of tax)  

 
 

  (315,996)  

 
 
 
 

  7,907  

 
 
 
 

  (283,235)  

 
 
 
 

  9,400  

 
 
 

  Adjusted net income attributable to Albemarle Corporation  

 
 

  $  

 
 

  104,331  

 
 
 
 

  $  

 
 

  91,232  

 
 
 
 

  $  

 
 

  228,502  

 
 
 
 

  $  

 
 

  197,618  

 
 
 
 
 
 
 
 
 
 
 

  Adjusted diluted earnings per share  

 
 

  $  

 
 

  0.89  

 
 
 
 

  $  

 
 

  0.86  

 
 
 
 

  $  

 
 

  1.98  

 
 
 
 

  $  

 
 

  1.86  

 
 
 
 
 
 
 
 
 
 
 

  Weighted-average common shares outstanding – diluted  

 
 

  117,436  

 
 
 
 

  106,535  

 
 
 
 

  115,383  

 
 
 
 

  106,524  

 
 
 
 
 
 
 
 
 
 
 

  Net income attributable to Albemarle Corporation  

 
 

  $  

 
 

  424,600  

 
 
 
 

  $  

 
 

  85,624  

 
 
 
 

  $  

 
 

  520,277  

 
 
 
 

  $  

 
 

  192,828  

 
 
 

  Add back:  

 
 
 
 
 
 
 
 
 

  Interest and financing expenses  

 
 

  7,152  

 
 
 
 

  17,852  

 
 
 
 

  51,034  

 
 
 
 

  34,737  

 
 
 

  Income tax expense  

 
 

  106,985  

 
 
 
 

  15,431  

 
 
 
 

  129,092  

 
 
 
 

  33,873  

 
 
 

  Depreciation and amortization  

 
 

  61,423  

 
 
 
 

  57,841  

 
 
 
 

  123,683  

 
 
 
 

  111,535  

 
 
 

   EBITDA   

 
 

  600,160  

 
 
 
 

  176,748  

 
 
 
 

  824,086  

 
 
 
 

  372,973  

 
 
 

  Non-operating pension and OPEB items  

 
 

  (5,471)  

 
 
 
 

  (2,895)  

 
 
 
 

  (10,936)  

 
 
 
 

  (5,803)  

 
 
 

  Non-recurring and other unusual items  

 
 

  (400,061)  

 
 
 
 

  11,340  

 
 
 
 

  (388,468)  

 
 
 
 

  14,388  

 
 
 

   Adjusted EBITDA   

 
 

  $  

 
 

  194,628  

 
 
 
 

  $  

 
 

  185,193  

 
 
 
 

  $  

 
 

  424,682  

 
 
 
 

  $  

 
 

  381,558  

 
 
 
 
 
 
 
 
 
 
 

  Net sales  

 
 

  $  

 
 

  773,896  

 
 
 
 

  $  

 
 

  764,049  

 
 
 
 

  $  

 
 

  1,603,187  

 
 
 
 

  $  

 
 

  1,502,894  

 
 
 

  EBITDA margin  

 
 

  77.6  

 
 

  %  

 
 
 

  23.1  

 
 

  %  

 
 
 

  51.4  

 
 

  %  

 
 
 

  24.8  

 
 

  %  

 
 

  Adjusted EBITDA margin  

 
 

  25.1  

 
 

  %  

 
 
 

  24.2  

 
 

  %  

 
 
 

  26.5  

 
 

  %  

 
 
 

  25.4  

 
 

  %  

 
 
 

 

 

See below for a reconciliation of adjusted EBITDA on a segment basis, the non-GAAP financial measure, to Net income attributable to Albemarle Corporation, the most directly comparable financial measure calculated and reported in accordance with GAAP (in thousands, except percentages).

 
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
 
 

   Lithium   

 
 
 

   Bromine
Specialties
 
 

 
 
 

   Catalysts   

 
 
 

   Reportable
Segments
Total
 
 

 
 
 

   All
Other
 
 

 
 
 

   Corporate   

 
 
 

   Consolidated
Total
 
 

 
 
 

   % of
Net
Sales
 
 

 
 

   Three months ended June 30, 2021   

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  Net income (loss) attributable to Albemarle Corporation  

 
 

  $  

 
 

  74,593  

 
 
 
 

  $  

 
 

  80,148  

 
 
 
 

  $  

 
 

  8,446  

 
 
 
 

  $  

 
 

  163,187  

 
 
 
 

  $  

 
 

  7,972  

 
 
 
 

  $  

 
 

  253,441  

 
 
 
 

  $  

 
 

  424,600  

 
 
 
 

  54.9  

 
 

  %  

 
 

  Depreciation and amortization  

 
 

  33,497  

 
 
 
 

  12,498  

 
 
 
 

  12,718  

 
 
 
 

  58,713  

 
 
 
 

  407  

 
 
 
 

  2,303  

 
 
 
 

  61,423  

 
 
 
 

  7.9  

 
 

  %  

 
 

  Non-recurring and other unusual items  

 
 

  1,351  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  1,351  

 
 
 
 

  

 
 
 
 

  (401,412)  

 
 
 
 

  (400,061)  

 
 
 
 

  (51.7)  

 
 

  %  

 
 

  Interest and financing expenses  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  7,152  

 
 
 
 

  7,152  

 
 
 
 

  0.9  

 
 

  %  

 
 

  Income tax expense  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  106,985  

 
 
 
 

  106,985  

 
 
 
 

  13.8  

 
 

  %  

 
 

  Non-operating pension and OPEB items  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  (5,471)  

 
 
 
 

  (5,471)  

 
 
 
 

  (0.7)  

 
 

  %  

 
 

   Adjusted EBITDA   

 
 

  $  

 
 

  109,441  

 
 
 
 

  $  

 
 

  92,646  

 
 
 
 

  $  

 
 

  21,164  

 
 
 
 

  $  

 
 

  223,251  

 
 
 
 

  $  

 
 

  8,379  

 
 
 
 

  $  

 
 

  (37,002)  

 
 
 
 

  $  

 
 

  194,628  

 
 
 
 

  25.1  

 
 

  %  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

   Three months ended June 30, 2020   

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  Net income (loss) attributable to Albemarle Corporation  

 
 

  $  

 
 

  66,038  

 
 
 
 

  $  

 
 

  60,692  

 
 
 
 

  $  

 
 

  10,702  

 
 
 
 

  $  

 
 

  137,432  

 
 
 
 

  $  

 
 

  16,425  

 
 
 
 

  $  

 
 

  (68,233)  

 
 
 
 

  $  

 
 

  85,624  

 
 
 
 

  11.2  

 
 

  %  

 
 

  Depreciation and amortization  

 
 

  28,498  

 
 
 
 

  12,349  

 
 
 
 

  12,075  

 
 
 
 

  52,922  

 
 
 
 

  2,173  

 
 
 
 

  2,746  

 
 
 
 

  57,841  

 
 
 
 

  7.6  

 
 

  %  

 
 

  Non-recurring and other unusual items  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  11,340  

 
 
 
 

  11,340  

 
 
 
 

  1.5  

 
 

  %  

 
 

  Interest and financing expenses  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  17,852  

 
 
 
 

  17,852  

 
 
 
 

  2.3  

 
 

  %  

 
 

  Income tax expense  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  15,431  

 
 
 
 

  15,431  

 
 
 
 

  2.1  

 
 

  %  

 
 

  Non-operating pension and OPEB items  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  (2,895)  

 
 
 
 

  (2,895)  

 
 
 
 

  (0.4)  

 
 

  %  

 
 

   Adjusted EBITDA   

 
 

  $  

 
 

  94,536  

 
 
 
 

  $  

 
 

  73,041  

 
 
 
 

  $  

 
 

  22,777  

 
 
 
 

  $  

 
 

  190,354  

 
 
 
 

  $  

 
 

  18,598  

 
 
 
 

  $  

 
 

  (23,759)  

 
 
 
 

  $  

 
 

  185,193  

 
 
 
 

  24.2  

 
 

  %  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

   Six months ended June 30, 2021   

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  Net income (loss) attributable to Albemarle Corporation  

 
 

  $  

 
 

  144,965  

 
 
 
 

  $  

 
 

  162,261  

 
 
 
 

  $  

 
 

  21,362  

 
 
 
 

  $  

 
 

  328,588  

 
 
 
 

  $  

 
 

  27,988  

 
 
 
 

  $  

 
 

  163,701  

 
 
 
 

  $  

 
 

  520,277  

 
 
 
 

  32.5  

 
 

  %  

 
 

  Depreciation and amortization  

 
 

  65,303  

 
 
 
 

  25,025  

 
 
 
 

  25,229  

 
 
 
 

  115,557  

 
 
 
 

  1,870  

 
 
 
 

  6,256  

 
 
 
 

  123,683  

 
 
 
 

  7.7  

 
 

  %  

 
 

  Non-recurring and other unusual items  

 
 

  5,609  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  5,609  

 
 
 
 

  

 
 
 
 

  (394,077)  

 
 
 
 

  (388,468)  

 
 
 
 

  (24.2)  

 
 

  %  

 
 

  Interest and financing expenses  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  51,034  

 
 
 
 

  51,034  

 
 
 
 

  3.2  

 
 

  %  

 
 

  Income tax expense  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  129,092  

 
 
 
 

  129,092  

 
 
 
 

  8.1  

 
 

  %  

 
 

  Non-operating pension and OPEB items  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  (10,936)  

 
 
 
 

  (10,936)  

 
 
 
 

  (0.7)  

 
 

  %  

 
 

   Adjusted EBITDA   

 
 

  $  

 
 

  215,877  

 
 
 
 

  $  

 
 

  187,286  

 
 
 
 

  $  

 
 

  46,591  

 
 
 
 

  $  

 
 

  449,754  

 
 
 
 

  $  

 
 

  29,858  

 
 
 
 

  $  

 
 

  (54,930)  

 
 
 
 

  $  

 
 

  424,682  

 
 
 
 

  26.5  

 
 

  %  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

   Six months ended June 30, 2020   

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  Net income (loss) attributable to Albemarle Corporation  

 
 

  $  

 
 

  119,278  

 
 
 
 

  $  

 
 

  132,357  

 
 
 
 

  $  

 
 

  45,594  

 
 
 
 

  $  

 
 

  297,229  

 
 
 
 

  $  

 
 

  37,271  

 
 
 
 

  $  

 
 

  (141,672)  

 
 
 
 

  $  

 
 

  192,828  

 
 
 
 

  12.8  

 
 

  %  

 
 

  Depreciation and amortization  

 
 

  53,895  

 
 
 
 

  23,946  

 
 
 
 

  24,653  

 
 
 
 

  102,494  

 
 
 
 

  4,151  

 
 
 
 

  4,890  

 
 
 
 

  111,535  

 
 
 
 

  7.4  

 
 

  %  

 
 

  Non-recurring and other unusual items  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  14,388  

 
 
 
 

  14,388  

 
 
 
 

  1.0  

 
 

  %  

 
 

  Interest and financing expenses  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  34,737  

 
 
 
 

  34,737  

 
 
 
 

  2.3  

 
 

  %  

 
 

  Income tax expense  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  33,873  

 
 
 
 

  33,873  

 
 
 
 

  2.3  

 
 

  %  

 
 

  Non-operating pension and OPEB items  

 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  

 
 
 
 

  (5,803)  

 
 
 
 

  (5,803)  

 
 
 
 

  (0.4)  

 
 

  %  

 
 

   Adjusted EBITDA   

 
 

  $  

 
 

  173,173  

 
 
 
 

  $  

 
 

  156,303  

 
 
 
 

  $  

 
 

  70,247  

 
 
 
 

  $  

 
 

  399,723  

 
 
 
 

  $  

 
 

  41,422  

 
 
 
 

  $  

 
 

  (59,587)  

 
 
 
 

  $  

 
 

  381,558  

 
 
 
 

  25.4  

 
 

  %  

 
 
 

 

 

Non-operating pension and OPEB items, consisting of mark-to-market actuarial gains/losses, settlements/curtailments, interest cost and expected return on assets, are not allocated to Albemarle's operating segments and are included in the Corporate category. In addition, the company believes that these components of pension cost are mainly driven by market performance, and the company manages these separately from the operational performance of the company's businesses. In accordance with GAAP, these non-operating pension and OPEB items are included in Other income (expenses), net. Non-operating pension and OPEB items were as follows (in thousands):

 
 
                                                            
 
 

   Three Months Ended   

 
 
 

   Six Months Ended   

 
 
 

   June 30,   

 
 
 

   June 30,   

 
 
 

   2021   

 
 
 

   2020   

 
 
 

   2021   

 
 
 

   2020   

 
 

  Interest cost  

 
 

  $  

 
 

  5,430  

 
 
 
 

  $  

 
 

  7,133  

 
 
 
 

  $  

 
 

  10,858  

 
 
 
 

  $  

 
 

  14,288  

 
 
 

  Expected return on assets  

 
 

  (10,901)  

 
 
 
 

  (10,028)  

 
 
 
 

  (21,794)  

 
 
 
 

  (20,091)  

 
 
 

  Total  

 
 

  $  

 
 

  (5,471)  

 
 
 
 

  $  

 
 

  (2,895)  

 
 
 
 

  $  

 
 

  (10,936)  

 
 
 
 

  $  

 
 

  (5,803)  

 
 
 
 

 

 

In addition to the non-operating pension and OPEB items disclosed above, the company has identified certain other items and excluded them from Albemarle's adjusted net income calculation for the periods presented. A listing of these items, as well as a detailed description of each follows below (per diluted share):

 
 
                                                                                                                        
 
 

   Three Months Ended   

 
 
 

   Six Months Ended   

 
 
 

   June 30,   

 
 
 

   June 30,   

 
 
 

   2021   

 
 
 

   2020   

 
 
 

   2021   

 
 
 

   2020   

 
 

  Restructuring and other (1)  

 
 

  $  

 
 

  

 
 
 
 

  $  

 
 

  0.04  

 
 
 
 

  $  

 
 

  0.01  

 
 
 
 

  $  

 
 

  0.06  

 
 
 

  Acquisition and integration related costs (2)  

 
 

  0.01  

 
 
 
 

  0.04  

 
 
 
 

  0.03  

 
 
 
 

  0.06  

 
 
 

  Albemarle Foundation contribution (3)  

 
 

  0.13  

 
 
 
 

  

 
 
 
 

  0.13  

 
 
 
 

  

 
 
 

  Gain on sale of business (4)  

 
 

  (2.82)  

 
 
 
 

  

 
 
 
 

  (2.87)  

 
 
 
 

  

 
 
 

  Loss on early extinguishment of debt (5)  

 
 

  0.01  

 
 
 
 

  

 
 
 
 

  0.21  

 
 
 
 

  

 
 
 

  Other (6)  

 
 

  0.04  

 
 
 
 

  (0.01)  

 
 
 
 

  0.10  

 
 
 
 

  (0.02)  

 
 
 

  Discrete tax items (7)  

 
 

  (0.06)  

 
 
 
 

  

 
 
 
 

  (0.06)  

 
 
 
 

  (0.01)  

 
 
 

  Total non-recurring and other unusual items  

 
 

  $  

 
 

  (2.69)  

 
 
 
 

  $  

 
 

  0.07  

 
 
 
 

  $  

 
 

  (2.45)  

 
 
 
 

  $  

 
 

  0.09  

 
 
 
 
 
                                                                         
 
 
 

  (1)  

 
 

  During the three and six months ended June 30, 2021, Albemarle recorded facility closure costs related to offices in Germany, and severance expenses in Germany and Belgium, in Selling, general and administrative expenses of $0.8 million and $1.5 million ($0.5 million and $1.1 million after income taxes, or less than $0.01 and $0.01 per share), respectively. In 2020, Albemarle recorded severance expenses as part of business reorganization plans, impacting each of its businesses and Corporate, primarily in the U.S., Germany and with its Jordanian joint venture partner. During the three months ended June 30, 2020, the company recorded expenses of $6.7 million ($4.7 million after income taxes, or $0.04 per share) in Selling, general and administrative expenses. During the six months ended June, 2020, the company recorded severance expenses in Cost of goods sold, Selling, general and administrative expenses and Net income attributable to noncontrolling interest of $0.7 million, $8.2 million and a $0.3 million gain ($6.2 million after income taxes, or $0.06 per share), respectively. The balance of unpaid severance is recorded in Accrued expenses and is expected to primarily be paid through 2021.  

 
 
 
 
 

  (2)  

 
 

  Costs related to the acquisition, integration and potential divestitures of various significant projects, recorded in Selling, general and administrative expenses for the three and six months ended June 30, 2021 were $1.9 million and $4.1 million ($1.5 million and $3.2 million after income taxes, or $0.01 and $0.03 per share), respectively, and for the three and six months ended June 30, 2020 were $5.5 million and $8.4 million ($4.2 million and $6.5 million after income taxes, or $0.04 and $0.06 per share), respectively.  

 
 
 
 
 

  (3)  

 
 

  Included in Selling, general and administrative expenses for the three and six months ended June 30, 2021 is a charitable contribution of $20.0 million ($15.5 million after income taxes, or $0.13 per share), using a portion of the proceeds received from the FCS divestiture, to the Albemarle Foundation, a non-profit organization that sponsors grants, health and social projects, educational initiatives, disaster relief, matching gift programs, scholarships and other charitable initiatives in locations where Albemarle's employees live and the company operates. This contribution is in addition to the normal annual contribution made to the Albemarle Foundation by the company, and is significant in size and nature in that it is intended to provide more long-term benefits in these communities.  

 
 
 
 
 

  (4)  

 
 

  Included in Gain on sale of business, for the three and six months ended June 30, 2021 is $429.4 million ($331.6 million after discrete income taxes, or $2.87 per share) related to the sale of the FCS business.  

 
 
 
 
 

  (5)  

 
 

  Included in Interest and financing expenses for the three and six months ended June 30, 2021 is a loss on early extinguishment of debt of $1.2 million and $29.0 million ($0.8 million and $23.8 million after income taxes, or $0.01 and $0.21 per share), respectively, representing the tender premiums, fees, unamortized discounts and unamortized deferred financing costs from the redemption of $1.5 billion in debt using the proceeds from the issuance of common stock.  

 
 
 
 
 

  (6)  

 
 

  Other adjustments for the three months ended June 30, 2021 included amounts recorded in:  

 
 
 

  

 
 

  Selling, general and administrative expenses - $4.0 million of a loss resulting from the sale of property, plant and equipment, $1.6 million of charges for an environmental reserve at a site not part of the company's operations and $1.4 million of expenses primarily related to non-routine labor and compensation related costs that are outside normal compensation arrangements.  

 
 
 

  

 
 

  Other income, net - $0.3 million of a gain resulting from the adjustment of indemnification obligations related to previously disposed businesses.  

 
 
 

  After income taxes, these charges totaled $4.9 million, or $0.04 per share.  

 
 
 
 
 

  Other adjustments for the six months ended June 30, 2021 included amounts recorded in:  

 
 
 

  

 
 

  Selling, general and administrative expenses - $6.0 million of expenses primarily related to non-routine labor and compensation related costs that are outside normal compensation arrangements, a $4.0 million loss resulting from the sale of property, plant and equipment and $1.6 million of charges for an environmental reserve at a site not part of the company's operations.  

 
 
 

  

 
 

  Other income, net - $3.6 million of expenses primarily related to asset retirement obligation charges to update an estimate at a site formerly owned by Albemarle.  

 
 
 

  After income taxes, these charges totaled $11.4 million, or $0.10 per share.  

 
 
 
 
 

  Other adjustments for the three months ended June 30, 2020 included amounts recorded in:  

 
 
 

  

 
 

  Other expenses, net - $0.9 million ($0.6 million after income taxes, or $0.01 per share) net gain primarily relating to the sale of idle properties in Germany.  

 
 
 
 
 

  Other adjustments for the six months ended June 30, 2020 included amounts recorded in:  

 
 
 

  

 
 

  Other expenses, net - $2.7 million gain resulting from the settlement of a legal matter related to a business sold and $0.8 million net gain primarily relating to the sale of idle properties in Germany, partially offset by a $0.8 million loss resulting from the adjustment of indemnifications related to previously disposed businesses.  

 
 
 

  After income taxes, these net gains totaled $1.7 million, or $0.02 per share.  

 
 
 
 

  (7)  

 
 

  Included in Income tax expense for the three and six months ended June 30, 2021 are discrete net tax benefits of $7.6 million, or $0.06 per share and $6.6 million, or $0.06 per share, respectively. The net benefit for the three months is primarily related to excess tax benefits realized from stock-based compensation arrangements and the revaluation of deferred taxes due to tax rate changes. The net benefit for the six months is primarily related to the release of a foreign valuation allowance, excess tax benefits realized from stock-based compensation arrangements, and the revaluation of deferred taxes due to tax rate changes, partially offset by tax expense due to an out-of-period adjustment regarding an overstated deferred tax liability for the three-month period ended December 31, 2017.  

 
 
 
 
 

  Included in Income tax expense for the three and six months ended June 30, 2020 are discrete net tax benefits of $0.5 million, or less than $0.01 per share, and $1.6 million, or $0.01 per share. The net benefit for the three months is primarily related to lapses in statute of limitations. The net benefit for the six months is primarily related to excess tax benefits realized from stock-based compensation arrangements.  

 
 
 

 

 

See below for a reconciliation of the adjusted effective income tax rate, the non-GAAP financial measure, to the effective income tax rate, the most directly comparable financial measure calculated and reported in accordance with GAAP (in thousands, except percentages).

 
 
                                                                                                                                                                        
 
 

   Income before
income taxes and
equity in net income
of unconsolidated
investments
 
 

 
 
 

   Income tax
expense
 
 

 
 
 

   Effective income
tax rate
 
 

 
 

   Three months ended June 30, 2021   

 
 
 
 
 
 
 

  As reported  

 
 

  $  

 
 

  535,195  

 
 
 
 

  $  

 
 

  106,985  

 
 
 
 

  20.0  

 
 

  %  

 
 

  Non-recurring, other unusual and non-operating pension and OPEB items  

 
 

  (404,383)  

 
 
 
 

  (84,114)  

 
 
 
 
 

  As adjusted  

 
 

  $  

 
 

  130,812  

 
 
 
 

  $  

 
 

  22,871  

 
 
 
 

  17.5  

 
 

  %  

 
 
 
 
 
 
 
 

   Three months ended June 30, 2020   

 
 
 
 
 
 
 

  As reported  

 
 

  $  

 
 

  88,075  

 
 
 
 

  $  

 
 

  15,431  

 
 
 
 

  17.5  

 
 

  %  

 
 

  Non-recurring, other unusual and non-operating pension and OPEB items  

 
 

  8,445  

 
 
 
 

  2,837  

 
 
 
 
 

  As adjusted  

 
 

  $  

 
 

  96,520  

 
 
 
 

  $  

 
 

  18,268  

 
 
 
 

  18.9  

 
 

  %  

 
 
 
 
 
 
 
 

   Six months ended June 30, 2021   

 
 
 
 
 
 
 

  As reported  

 
 

  $  

 
 

  658,489  

 
 
 
 

  $  

 
 

  129,092  

 
 
 
 

  19.6  

 
 

  %  

 
 

  Non-recurring, other unusual and non-operating pension and OPEB items  

 
 

  (370,457)  

 
 
 
 

  (78,682)  

 
 
 
 
 

  As adjusted  

 
 

  $  

 
 

  288,032  

 
 
 
 

  $  

 
 

  50,410  

 
 
 
 

  17.5  

 
 

  %  

 
 
 
 
 
 
 
 

   Six months ended June 30, 2020   

 
 
 
 
 
 
 

  As reported  

 
 

  $  

 
 

  203,548  

 
 
 
 

  $  

 
 

  33,873  

 
 
 
 

  16.6  

 
 

  %  

 
 

  Non-recurring, other unusual and non-operating pension and OPEB items  

 
 

  8,906  

 
 
 
 

  3,795  

 
 
 
 
 

  As adjusted  

 
 

  $  

 
 

  212,454  

 
 
 
 

  $  

 
 

  37,668  

 
 
 
 

  17.7  

 
 

  %  

 
 
 

 

 
 
 

 Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/albemarle-reports-second-quarter-results-301348671.html  

 

SOURCE Albemarle Corporation

 
 

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Metallic battery with a world map etched on it, against a dark background.

3 Key Themes from Fastmarkets' 2025 Lithium Supply & Battery Raw Materials Event

Market volatility, Chinese control, supply chain risk mitigation and financing emerged as some of the most prevalent themes at the 2025 Fastmarket’s Lithium Supply Battery Raw Materials (LBRM) conference in Las Vegas.

The event, which is in its 17th year, drew a crowd of roughly 1000 delegates, industry experts and analysts, to discuss the current landscape and future projections of the battery materials sector.

During his opening remarks, Fastmarkets CEO Raju Daswani highlighted the growth and maturation the battery raw materials sector has experienced.

Keep reading...Show less
Metals Australia (ASX:MLS)

Metals Australia


Keep reading...Show less
Futuristic skyline with electric car chargers and glowing cityscape at sunset.

Expert: African Lithium Key to China's Battery Supply Chain Dominance

With the global shift to electric vehicles (EVs) accelerating, China is cementing its dominance over the lithium supply chain by pouring investment into African mines, creating a new center of gravity for the battery metal.

Speaking at the Lithium Supply Battery Raw Materials conference, Claudia Cook senior analyst at Fastmarkets offered a sweeping assessment of how China is reshaping global lithium flows and why Africa will be crucial in the next decade.

Cook laid out in detail how China’s lithium strategy is evolving. As the world’s largest EV market, China needs a consistent, low-cost supply of lithium — but its domestic production is increasingly insufficient.

Keep reading...Show less
Electric vehicle charging with blue background.

Market Pain, Strategic Gain: Pilbara Minerals' Dale Henderson on Today's Lithium Paradox

“(Lithium) is not for the faint-hearted. It demands resilience, foresight and leadership,” said Pilbara Minerals (ASX:PLS,OTC Pink:PILBF) Managing Director and CEO Dale Henderson.

He was speaking at Fastmarkets’ Lithium Supply & Battery Raw Materials Conference, held this week in Las Vegas.

Henderson touched on three main points: current lithium market dynamics, how Pilbara Minerals is navigating the lithium landscape and his recommendations for the global lithium industry.

Keep reading...Show less
Glowing battery with green zigzag on a futuristic circuit board background.

Fastmarkets’ 2025 Lithium Conference to Tackle EV Growth, Battery Supply Chains and Market Outlook

Fastmarkets is set to host its 17th Lithium Supply and Battery Raw Materials Conference.

Scheduled to run from June 23 to 26 in Las Vegas, Nevada, the event will bring together global industry leaders to explore key topics shaping the future of the battery supply chain.

Discussions will cover lithium extraction technologies, including direct lithium extraction, as well as advances in processing, refining and recycling. More broadly, market outlooks, pricing trends and investment strategies will be analyzed alongside evolving ESG standards, policy impacts and risk management approaches.

Keep reading...Show less
Gina Rinehart, executive chair of Hancock Prospecting, stands in front of cherry blossom trees.

Inside Billionaire Gina Rinehart's Key Mining Investments

Australian billionaire Gina Rinehart has become a formidable force in the global mining industry. 

After taking the helm of her father’s iron ore firm Hancock Prospecting in 1993, she embarked upon a diversification strategy that has vastly expanded her resource empire. Now Australia’s richest person, Rinehart has investments in many of the world’s most strategic commodities such as lithium, rare earths, copper, potash and natural gas.

One of those investments is Arafura Rare Earths (ASX:ARU,OTC Pink:ARAFF), which even in a low price environment for rare earths managed to secure nearly AU$1.5 billion in debt financing in mid-2024 to advance its Nolans project in the Northern Territory. With a 10 percent equity stake, Rinehart’s Hancock Prospecting is Arafura's largest shareholder.

Keep reading...Show less

Latest Press Releases

Related News

×